FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Yuvezzi™ (carbachol and brimonidine tartrate) dual-agent eyedrops: a new option for presbyopia. PMID 42078642 · Ann Med Surg (Lond) · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial. PMID 42069411 · Lancet Haematol · 2026-May The study is an oncology, human, randomized, phase 3, drug-intervention trial with original results. However, it fails the explicit time-to-event criterion. The primary endpoint is MR4.5, a molecular response rate (not time-to-event). No OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR is mentioned in the abstract. Therefore, is_eligible is null as metadata cannot establish the time_to_event criterion. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials. PMID 42061373 · Lancet Oncol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. PMID 42061371 · Lancet Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia. PMID 42053463 · J Clin Pharmacol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers. PMID 42053460 · J Clin Pharmacol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effects of romosozumab on bone strength around a pedicle screw as evaluated by biomechanical computed tomography-based virtual stress tests in postmenopausal women. PMID 42051047 · Spine J · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag. PMID 42047558 · NEJM Evid · 2026-May The study is a Phase 3 randomized trial with a drug intervention, but it does not report on a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or include Kaplan-Meier or HR analyses. The endpoint is a biomarker analysis (clonal hematopoiesis dynamics). |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. PMID 42047557 · NEJM Evid · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study. PMID 42044230 · Stroke · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of the Oncologist's Recommendation on Exercise Levels and Quality of Life in Patients With Lung Cancer: The ORE Randomized Controlled Trial. PMID 42036773 · Cancer Med · 2026-May This is an oncology randomized trial in humans, but it does not meet the core eligibility criteria. It is not a drug-containing intervention trial (the intervention is an exercise recommendation/guidebook). Furthermore, it does not have a time-to-event efficacy endpoint such as OS, PFS, or DFS; its primary endpoints are changes in exercise behavior and quality-of-life scores. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial. PMID 42026265 · Nat Med · 2026-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study. PMID 42021476 · Expert Opin Biol Ther · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial. PMID 42019090 · EBioMedicine · 2026-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Protocol for a pilot-randomized trial in newly diagnosed glioblastoma: standard care with or without daily intranasal perillyl alcohol. PMID 42015796 · Future Oncol · 2026-May 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Interleukin-23 Inhibitors in Inflammatory Bowel Disease. PMID 42012779 · BioDrugs · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Remote ischaemic conditioning in patients with supratentorial intracerebral haemorrhage (RICH-2): a multicentre, randomised, sham-controlled phase 3 trial in China. PMID 42011250 · EClinicalMedicine · 2026-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202. PMID 42006401 · Adv Radiat Oncol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study). PMID 42006277 · JTO Clin Res Rep · 2026-May The record is an updated biomarker analysis from a phase 3 trial, but it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier estimates or hazard ratios. The analysis focuses on circulating tumor DNA metrics and mutation rates. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial. PMID 41997828 · Clin Lung Cancer · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis. PMID 41996022 · Target Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial. PMID 41985366 · Thromb Res · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors. PMID 41982071 · Leuk Lymphoma · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children's Oncology Group randomized trial ACCL1033. PMID 41975001 · Leukemia · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. PMID 41969015 · Lancet Oncol · 2026-May The report is a secondary analysis from a Phase III RCT focusing on pain and quality-of-life endpoints, not the primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) required for inclusion. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease. PMID 41964731 · Ophthalmol Ther · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial. PMID 41962984 · Lancet Child Adolesc Health · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema: 1-Year Results from the China RHINE Subpopulation. PMID 41961203 · Ophthalmol Ther · 2026-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Drainage of Pleural Effusion in the Intensive Care Unit (DOPE-ICU) Feasibility Trial-Protocol and Statistical Analysis Plan. PMID 41952333 · Acta Anaesthesiol Scand · 2026-May The record describes a feasibility protocol for a randomized trial in ICU patients with pleural effusion. It is not an oncology study, does not involve a drug intervention (it is a procedural intervention), is not a Phase II/III or Phase III/IIIb trial (it's a feasibility study), and lacks a primary time-to-event efficacy endpoint. The report is a protocol without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE. PMID 41937506 · Liver Int · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis. PMID 41936375 · Lancet HIV · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association Between Survival Benefits of Anticancer Drugs and Probability of US Food and Drug Administration Approval: A Systematic Review. PMID 41915314 · Pharmaceut Med · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial. PMID 41910921 · Breast Cancer · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial. PMID 41905323 · Gynecol Oncol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical Trial Comparison of Dupilumab and Nemolizumab for Prurigo Nodularis FDA-Approved Biologic Therapy Selection in Prurigo Nodularis. PMID 41903084 · Clin Drug Investig · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial. PMID 41887242 · Lancet Respir Med · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial. PMID 41887239 · Lancet Gastroenterol Hepatol · 2026-May 干预为非药物单独策略,未满足药物干预要求。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies. PMID 41883115 · J Gastroenterol Hepatol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells. PMID 41882992 · Br J Haematol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. PMID 41881047 · Lancet Respir Med · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial. PMID 41876649 · Nat Med · 2026-May The study is a randomized, multicenter, oncology trial in humans, reporting original results. However, it is excluded because it does not involve a drug-containing intervention (it evaluates an AI diagnostic tool) and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary outcomes are process metrics (time to CT, time to diagnosis) and not survival or time-to-event endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). PMID 41874851 · Adv Ther · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial. PMID 41871353 · Ann Intern Med · 2026-May The trial is a randomized Phase III study in human oncology (breast cancer) with a drug intervention (pegfilgrastim). However, the primary and secondary endpoints are not time-to-event efficacy measures (OS, PFS, DFS, etc.). The primary endpoint is the AUC of a daily pain score, and secondary endpoints are incidence rates of pain, neutropenia, and febrile neutropenia. No Kaplan-Meier, hazard ratio, or other time-to-event analysis is reported. Therefore, it does not meet the time-to-event criterion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Music Intervention on Pain, Anxiety, and Vital Signs in Radiotherapy Patients: A Randomized Controlled Trial Based on the Roy Adaptation Model. PMID 41871042 · Clin Nurs Res · 2026-May The study is excluded because it is a non-drug, non-oncology-directed Phase III trial with non-time-to-event endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03. PMID 41870844 · Ophthalmol Ther · 2026-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The whole-course of supervised home-based multi-modal prehabilitation to improve clinical outcome in patients undergoing neoadjuvant chemotherapy prior to gastrectomy: a single-center randomized controlled trial. PMID 41870736 · Gastric Cancer · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study. PMID 41870735 · Gastric Cancer · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Assessing and Listening to Individual Goals and Needs (ALIGN) versus enhanced usual care for hospitalized older patients with cancer discharged to skilled nursing facilities: Protocol for a pilot randomized controlled trial. PMID 41861729 · J Geriatr Oncol · 2026-May 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comment on low-dose fractionated radiotherapy during induction chemotherapy for node-positive locoregionally advanced nasopharyngeal carcinoma: a randomized phase II trial. PMID 41861716 · Oral Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mycophenolate mofetil versus prednisone for the initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children in Germany (INTENT): a multicentre, open-label, randomised, controlled, parallel-group, non-inferiority, phase 3 trial. PMID 41856160 · Lancet Child Adolesc Health · 2026-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |